Olopatadine Eye Drops and Allergy Skin Testing

Completed · Not applicable · Has a placebo group

Conditions studied: Allergic Rhinitis, Allergic Conjunctivitis

In brief

Use of olopatadine ophthalmic solution (eye drops) will decrease allergy skin test reactivity.

Key facts

Study ID

NCT00775658

Run by

Vanderbilt University Medical Center

People needed

24

Starts

2008-01-01

Expected to finish

2008-06-01

Last updated by the study team

2017-07-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults aged 18 to 75 years
• Healthy volunteers (no major illnesses or active symptoms)

You may not qualify if…

• Known allergy or hypersensitivity to the drugs or components
• Pregnant or nursing women
• Women wishing to become pregnant during the study's duration
• Use of topical or oral medications with antihistaminic activity for 14 days proceeding randomization
• Dermatographism as evidenced on skin testing on visit 1
• Chronic urticaria active within the past 6 months
• Severe hypertension
• Psychiatric diagnoses which could potentially affect medication compliance, such as schizophrenia or delusional disorders, as determined by the investigator obtaining informed consent and based on the subject's past medical history
• Inability to provide informed consent

Where it is running

• Vanderbilt Asthma, Sinus and Allergy Program Research — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.